IP Library › Granted Patent US 12,692,317
Granted Patent B2
US 12,692,317 · App. 18/017,531 · Granted Jul 28, 2026

IL12RB2 binding molecules and methods of use

Inventors: Sandro Vivona (Menlo Park, CA); Robert Kastelein (Menlo Park, CA); Deepti Rokkam (Menlo Park, CA); Patrick J. Lupardus (Menlo Park, CA)
Assignee: Synthekine, Inc.
C07K16/2866A61P37/02C07K14/7155C07K16/2803C07K16/46C07K16/468C07K19/00C12N15/63C12N15/86A61K2039/505C07K2317/22C07K2317/24C07K2317/31C07K2317/33C07K2317/522C07K2317/524C07K2317/526C07K2317/53C07K2317/565C07K2317/567C07K2317/569C07K2319/40
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,692,317
App. No.
18/017,531
Filed
Jan 23, 2023
Granted
Jul 28, 2026
Kind
B2
Art Unit
1641
USPC
424/133.1
Abstract

The present disclosure relates to biologically active molecules comprising a single domain antibody (sdAb) that specifically binds to the extracellular domain of human IL12Rb2, compositions comprising such antibodies, and methods of use thereof.

Claims (226)

1 . A IL12Rb2 binding molecule that specifically binds to the extracellular domain of IL12Rb2, wherein the IL12Rb2 binding molecule comprises a single domain antibody (sdAb), wherein the sdAb comprises a complementary determining region 1 (CDR1), a CDR2, and a CDR3 as shown in a row of the table below:

CDR1

CDR2

CDR3

FTVTRYC

IIERDGRTGY

IEGSCRP

MG

ADSVKG

DFGY

(SEQ ID

(SEQ ID

(SEQ ID

NO: 20)

NO: 21)

NO: 22)

FTISRYC

IIERDGRTGY

IEGSCRPD

MG

ADSVKG

FGY

(SEQ ID

(SEQ ID

(SEQ ID

NO: 23)

NO: 24)

NO: 25)

LTFDDVE

SINTDSRVYY

DPWGGDLR

MA

VDSVKD

GYPNY

(SEQ ID

(SEQ ID

(SEQ ID

NO: 26)

NO: 27)

NO: 28)

FTISRYC

IIERDGRTGY

IEGSCRPD

MG

ADSVKG

FGY

(SEQ ID

(SEQ ID

(SEQ ID

NO: 29)

NO: 30)

NO: 31)

FTFSTYA

RISSGGGNTY

DDYYGGSW

MS

YADAVKG

HPIS

(SEQ ID

(SEQ ID

(SEQ ID

NO: 32)

NO: 33)

NO: 34)

YTYGLFC

VVDSPGGRHV

DPEKYCFL

MG

ADSLKG

FSDAGYQY

(SEQ ID

(SEQ ID

(SEQ ID

NO: 35)

NO: 36)

NO: 37)

VTYSRYC

TIYSRGIITY

TRETYG

MG

YTDSVKG

GSG

(SEQ ID

(SEQ ID

DCDYESV

NO: 38)

NO: 39)

YNY

(SEQ ID

NO: 40)

FTVSRYC

IIEREGRTGY

IEGSCRPD

MG

ADSVKG

FGY

(SEQ ID

(SEQ ID

(SEQ ID

NO: 41)

NO: 42)

NO: 43)

FTISRYC

IIERDGRTGY

IEGSCRPD

MG

ADSVKG

FGY

(SEQ ID

(SEQ ID

(SEQ ID

NO: 44)

NO: 45)

NO: 46)

FTVTRYC

IIERDGRTGY

IEGSCRPD

MG

ADSVKG

FGY

(SEQ ID

(SEQ ID

(SEQ ID

NO: 47)

NO: 48)

NO: 49)

FTVSRY

IIERDGRTGY

IEGSCRPD

CMG

ADSVKG

FGY

(SEQ ID

(SEQ ID

(SEQ ID

NO: 50)

NO: 51)

NO: 52)

VTYSRYCMG

TIYSRGI

TRETYGGS

(SEQ ID

ITYYTDS

GDCDYES

NO: 53)

VKG

VYNY

(SEQ ID

(SEQ ID

NO: 54)

NO: 55)

FTISKYC

IIERDGRTG

IEGSCRPD

MG

YADSVKG

FGY

(SEQ ID

(SEQ ID

(SEQ ID

NO: 56)

NO: 57)

NO: 58)

VTYSRYCMG

HIYSRGI

TRETYGGS

(SEQ ID

ITYYTDS

GDCGYESV

NO: 59)

VKG

YNY

(SEQ ID

(SEQ ID

NO: 60)

NO: 61)

FTISRYC

IIERDGRTGYA

IEGSCRP

MG

DSVKG

DLGY

(SEQ ID

(SEQ ID

(SEQ ID

NO: 62)

NO: 63)

NO: 64)

VTYSRYCMG

HIYSRGIITY

TRETYGGSGD

(SEQ ID

YTDSVKG

CSYESVYNH

NO: 65)

(SEQ ID

(SEQ ID

NO: 66)

NO: 67)

LTISRYC

IIERDGRTGYA

IEGSCRP

MG

DSVKG

DFGY

(SEQ ID

(SEQ ID

(SEQ ID

NO: 68)

NO: 69)

NO: 70)

FTVDDFA

TISSGGSTYYA

SSVGCPL

MG

DSVKG

GY

(SEQ ID

(SEQ ID

(SEQ ID

NO: 71)

NO: 72)

NO: 73)

2 . The IL12Rb2 binding molecule of claim 1 wherein the sdAb has at least 80% identity to a polypeptide sequence of any one of SEQ ID NOS: 2-19.

3 . The IL12Rb2 binding molecule of claim 1 , wherein the sdAb is humanized or otherwise comprises CDRs grafted onto a heterologous framework.

4 . The IL12Rb2 binding molecule of claim 1 , further comprising a labeling agent, an imaging agent, and/or a therapeutic agent.

Assignments (2)
CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNEE'S NAME PREVIOUSLY RECORDED AT REEL: 62954 FRAME: 174. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT . Recorded Jun 11, 2026
From: KASTELEIN, ROBERT; ROKKAM, DEEPTI; LUPARDUS, PATRICK J.; VIVONA, SANDRO
To: SYNTHEKINE, INC.
Reel/Frame 075811/0067 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 12, 2023
From: KASTELEIN, ROBERT; ROKKAM, DEEPTI; LUPARDUS, PATRICK J.; VIVONA, SANDRO
To: INC., SYNTHEKINE
Reel/Frame 062954/0174 →
Continuity (4)
Provisional Application 63061562 · Aug 5, 2020
Provisional Application 63078745 · Sep 15, 2020
Provisional Application 63135884 · Jan 11, 2021
Related Publication 20230357414A1 · Nov 9, 2023
References Cited (83)
US 5843708A · Hardman · 1998 [cited by examiner]
US 8258268B2 · Wu et al. · 2012 [cited by applicant]
US 8574573B2 · Carballido Herrera et al. · 2013 [cited by applicant]
US 8921528B2 · Holt et al. · 2014 [cited by applicant]
US 8975382B2 · Revets et al. · 2015 [cited by applicant]
US 10927186B2 · Roobrouck et al. · 2021 [cited by applicant]
US 11859001B2 · Kastelein et al. · 2024 [cited by applicant]
US 12012457B1 · Kastelein et al. · 2024 [cited by applicant]
US 12291572B2 · Kastelein · 2025 [cited by examiner]
US 20060024295A1 · Brunetta · 2006 [cited by applicant]
US 20100297127A1 · Ghilardi et al. · 2010 [cited by applicant]
US 20110028695A1 · Revets et al. · 2011 [cited by applicant]
US 20110053865A1 · Saunders et al. · 2011 [cited by applicant]
US 20110142831A1 · Cua et al. · 2011 [cited by applicant]
US 20120082681A1 · Carballido et al. · 2012 [cited by applicant]
US 20120201746A1 · Liu et al. · 2012 [cited by applicant]
US 20120316324A1 · Adams et al. · 2012 [cited by applicant]
US 20140065142A1 · Roschke et al. · 2014 [cited by applicant]
US 20140099708A1 · Carballido Herrera et al. · 2014 [cited by applicant]
US 20140170154A1 · Presta · 2014 [cited by applicant]
US 20150079088A1 · Lowman et al. · 2015 [cited by applicant]
US 20160046730A1 · Ghayur et al. · 2016 [cited by applicant]
US 20160251440A1 · Roobrouck et al. · 2016 [cited by applicant]
US 20170106051A1 · Oh et al. · 2017 [cited by applicant]
US 20170298149A1 · Baeuerle et al. · 2017 [cited by applicant]
US 20180362655A1 · Wang et al. · 2018 [cited by applicant]
US 20190315864A1 · Xu et al. · 2019 [cited by applicant]
US 20200157237A1 · Regev et al. · 2020 [cited by applicant]
US 20230272093A1 · Kastelein et al. · 2023 [cited by applicant]
CN 103396482A · 2013 [cited by applicant]
CN 111018985A · 2020 [cited by applicant]
WO 2008011081A2 · 2008 [cited by applicant]
WO 2009068631A1 · 2009 [cited by applicant]
WO 2011051327A2 · 2011 [cited by applicant]
WO 2013006544A1 · 2013 [cited by applicant]
WO 2013059299A1 · 2013 [cited by applicant]
WO 2016097313A1 · 2016 [cited by applicant]
WO 2017198212A1 · 2017 [cited by applicant]
WO 2019129221A1 · 2019 [cited by applicant]
WO 2020052543A1 · 2020 [cited by applicant]
WO 2020144164A1 · 2020 [cited by applicant]
WO 2020187711A1 · 2020 [cited by applicant]
WO 2022031929A1 · 2022 [cited by applicant]
WO 2022031942A2 · 2022 [cited by applicant]
WO 2022032037A1 · 2022 [cited by applicant]
WO 2022032042A1 · 2022 [cited by applicant]
WO 2022055641A2 · 2022 [cited by applicant]
De Genst et al. Developmental and Comparative Immunology 30(2006) 187-198. (Year: 2006). [cited by examiner]
Tereshko et al. Protein Science. 2008, 17:1175-1187. (Year: 2008). [cited by examiner]
Deschacht et al. The Journal of Immunology, 2010, 184:5696-5704. (Year: 2010). [cited by examiner]
Sircar et al. The Journal of Immunology 2011, 186:6357-6367. (Year: 2011). [cited by examiner]
Tait Wojno et al. Immunity 2019, 50:851-870. (Year: 2019). [cited by examiner]
“PE Anti-Mouse IL-23R Antibody”, BioLegend, Available Online at: https://biolegend.com/en-us/global-elements/pdf-popup/pe-anti-mouse-il-23r-antibody-13084?filename=PE%20anti-mouse%201L-23R%20Antibody.pdf&pdfoen=true, Ma… [cited by applicant]
“UniProtKB-A0A066RQT8”, Uncharacterized Protein, Available Online at: https://www.uniprot.org/uniprot/A0A066RQT8, Sep. 3, 2014, 3 pages. [cited by applicant]
U.S. Appl. No. 18/006,528 , Notice of Allowance, Mailed on Dec. 20, 2023, 7 pages. [cited by applicant]
U.S. Appl. No. 18/017,065 , Non-Final Office Action, Mailed on Sep. 19, 2023, 8 pages. [cited by applicant]
U.S. Appl. No. 18/017,065 , Notice of Allowance, Mailed on Feb. 7, 2024, 8 pages. [cited by applicant]
U.S. Appl. No. 18/017,282 , Notice of Allowance, Mailed on Aug. 24, 2023, 14 pages. [cited by applicant]
U.S. Appl. No. 18/017,836 , Non-Final Office Action, Mailed on May 10, 2024, 11 pages. [cited by applicant]
U.S. Appl. No. 18/017,838 , Non-Final Office Action, Mailed on Jul. 9, 2024, 13 pages. [cited by applicant]
U.S. Appl. No. 18/018,444 , Final Office Action, Mailed on Jun. 14, 2024, 8 pages. [cited by applicant]
U.S. Appl. No. 18/018,444 , Non-Final Office Action, Mailed on Feb. 1, 2024, 14 pages. [cited by applicant]
U.S. Appl. No. 18/018,448 , Advisory Action, Mailed on May 9, 2024, 3 pages. [cited by applicant]
U.S. Appl. No. 18/018,448 , Final Office Action, Mailed on Feb. 26, 2024, 12 pages. [cited by applicant]
U.S. Appl. No. 18/018,448 , Non-Final Office Action, Mailed on Jul. 8, 2024, 10 pages. [cited by applicant]
U.S. Appl. No. 18/018,448 , Non-Final Office Action, Mailed on Sep. 25, 2023, 18 pages. [cited by applicant]
U.S. Appl. No. 18/514,330 , Non-Final Office Action, Mailed on Aug. 7, 2024, 15 pages. [cited by applicant]
Donnelly et al., “The Expanded Family of Class II Ctokines that Share the IL-10 Receptor-2 (IL-10R2) Chain”, Experimental Biology and Medicine (Maywood), vol. 244, No. 17, Dec. 2019, pp. 1568-1576. [cited by applicant]
Franke et al., “Human and Murine Interleukin 23 Receptors are Novel Substrates for a Disintegrin and Metalloproteases ADAM10 and ADAM17”, The Journal of Biological Chemistry, vol. 291, No. 20, May 13, 2016, pp. 10551-10… [cited by applicant]
Application No. PCT/US2021/044674 , International Preliminary Report on Patentability, Mailed on Feb. 16, 2023, 8 pages. [cited by applicant]
Application No. PCT/US2021/044674 , International Search Report and Written Opinion, Mailed on Jan. 19, 2022, 12 pages. [cited by applicant]
PCT/US2021/044674 , “Invitation to Pay Additional Fees and, Where Applicable, Protest Fee”, Nov. 12, 2021, 2 pages. [cited by applicant]
Application No. PCT/US2021/044698 , International Preliminary Report on Patentability, Mailed on Feb. 16, 2023, 9 pages. [cited by applicant]
Application No. PCT/US2021/044835 , International Search Report and Written Opinion, Mailed on Feb. 8, 2022, 17 pages. [cited by applicant]
PCT/US2021/044835 , “Invitation to Pay Additional Fees and, Where Applicable, Protest Fee”, Nov. 16, 2021, 3 pages. [cited by applicant]
Application No. PCT/US2021/044850 , International Preliminary Report on Patentability, Mailed on Feb. 16, 2023, 6 pages. [cited by applicant]
Application No. PCT/US2021/044850 , International Search Report and Written Opinion, Mailed on Jan. 6, 2022, 9 pages. [cited by applicant]
Application No. PCT/US2021/044855 , International Preliminary Report on Patentability, Mailed on Feb. 16, 2023, 8 pages. [cited by applicant]
Application No. PCT/US2021/044855 , International Search Report and Written Opinion, Mailed on Dec. 16, 2021, 11 pages. [cited by applicant]
Pingwara et al., “IFN-λ Modulates the Migratory Capacity of Canine Mammary Tumor Cells via Regulation of the Expression of Matrix Metalloproteinases and their Inhibitors”, Cells, vol. 10, No. 5, Apr. 23, 2021, pp. 1-15. [cited by applicant]
Wilton et al., “sdAb-DB: The Single Domain Antibody Database”, American Chemical Society Synthetic Biology, vol. 7, No. 11, Nov. 16, 2018, pp. 2480-2484. [cited by applicant]
Hoey et al., “The Expanded Family of Class II Ctokines that Share the IL-10 Receptor-2 (IL-10R2) Chain”, Experimental Biology and Medicine (Maywood), vol. 244, No. 17, Dec. 2019, pp. 1568-1576. [cited by applicant]
International Patent Application No. PCT/US2021/044698 , “International Search Report and Written Opinion”, Feb. 1, 2022, 13 pages. [cited by applicant]